Gapping up
In reaction to strong earnings/guidance: ASTI +34%, TCS +5.7%, CCF +1.9%, HVT +1.1%, (Q2 sales)
Other news: PIP +5% (PharmAthene and Immunovaccine enter into an exclusive global license agreement), MHR +3.7% (received and accepted a firm commitment from Bank of Montreal, which is the administrative agent and lead lender under MHR's senior secured revolving credit facility), VNDA +3.5% (receives European Commission approval for HETLIOZ (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder in totally blind adults ), SYMC +3.1% (close to deal for Veritas unit sale to Carlyle (CG) for $7-8 bln, according to Bloomberg), TREE +3% (to replace MIG in the S&P SmallCap 600), TI +2.8% (still checking), IRWD +2.5% (Ironwood Pharma and AstraZeneca announce that top-line data demonstrate linaclotide met all primary and secondary endpoints), BTU +2.2% (Wyoming Department of Environmental Quality reaffirmed self-bonding eligibility for three mine permits), GLDD +1.9% (announced the receipt of a $76 mln award for the Shell Island West Natural Resource Damage Assessment Restoration Project; also recently awarded a $20 mln contract), ARWR +1.9% (receives regulatory permission in the UK and New Zealand to proceed with Part B of its Phase 1 study of ARC-AAT), BBW +1% ( adopts a new repurchase program which authorizes the Company to repurchase up to an additional $10 million of its common stock until March 31, 2016)
Analyst comments: WWE +2.8% (initiated with a Outperform at Wells Fargo ), SNAK +2.5% (upgraded to Outperform from Neutral at Wedbush), DKS +1.1% (upgraded to Outperform at Imperial Capital), AGO +0.9% (upgraded to Buy from Neutral at BTIG Research
)
In reaction to strong earnings/guidance: ASTI +34%, TCS +5.7%, CCF +1.9%, HVT +1.1%, (Q2 sales)
Other news: PIP +5% (PharmAthene and Immunovaccine enter into an exclusive global license agreement), MHR +3.7% (received and accepted a firm commitment from Bank of Montreal, which is the administrative agent and lead lender under MHR's senior secured revolving credit facility), VNDA +3.5% (receives European Commission approval for HETLIOZ (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder in totally blind adults ), SYMC +3.1% (close to deal for Veritas unit sale to Carlyle (CG) for $7-8 bln, according to Bloomberg), TREE +3% (to replace MIG in the S&P SmallCap 600), TI +2.8% (still checking), IRWD +2.5% (Ironwood Pharma and AstraZeneca announce that top-line data demonstrate linaclotide met all primary and secondary endpoints), BTU +2.2% (Wyoming Department of Environmental Quality reaffirmed self-bonding eligibility for three mine permits), GLDD +1.9% (announced the receipt of a $76 mln award for the Shell Island West Natural Resource Damage Assessment Restoration Project; also recently awarded a $20 mln contract), ARWR +1.9% (receives regulatory permission in the UK and New Zealand to proceed with Part B of its Phase 1 study of ARC-AAT), BBW +1% ( adopts a new repurchase program which authorizes the Company to repurchase up to an additional $10 million of its common stock until March 31, 2016)
Analyst comments: WWE +2.8% (initiated with a Outperform at Wells Fargo ), SNAK +2.5% (upgraded to Outperform from Neutral at Wedbush), DKS +1.1% (upgraded to Outperform at Imperial Capital), AGO +0.9% (upgraded to Buy from Neutral at BTIG Research
)